Drugs / P.vivax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03474822 | Aug 2018 → Jun 2023 | breast cancer, liver cancer | CAS Lamvac Biotech Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P.vivax | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03474822 ↗ |